Did you not read/listen to the last week's updates?? Arikace has met its end-point and is comparable to TOBI (the gold standard in CF treatment) with the convenience of half the number of dosages per day. Also, during the course of the study, Arikace continued to show incremental improvement while TOBI did not.
What do you mean 40% down?? INSM is up over 300% over the last 52 weeks.
Ah, someone who sees what happens by month 3! The 110 will be the ultimate determinate of the Pa impact, but the 1/day will make for better treatment regimen. What people fail to realize is that compared to real world use of Tobi, Arikace 1/day would like yield better FEV1 results overtime. You can bet with the trial design for non-inferiority, the bashers were already lining up with the "failed to show superiority" argument and bash. This will make market and with NTM, Arikace will generate some nice revenue. What the bashers need to focus on now is money to bring to market and rev up the pipeline, one-product company.
yahoo says you have been in Insmed from 2005 and I say you have lost 40%. I m telling the truth
My shares were from the iplex era of hype here. Arikace disappointed with average results and if you do not believe me look at the share price. Unlike you I don't believe every hype that comes your way.
I bet arikace either gets bought for a cheap price or TOBI competitors let Insmed twist slowly in the wind.